Pharming Group N.V.(PHAR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAR Pharming Group N.V.

Trading 03-28 13:31:13 EDT

8.66

+0.19

+2.24%

High8.66	Low8.66	Vol1.82K
Open8.66	D1 Closing8.47	Amplitude0.00%
Mkt Cap589.15M	Tradable Cap570.28M	Total Shares68.03M
T/O15.80K	T/O Rate0.00%	Tradable Shares65.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"PHAR","market":"US","secType":"STK","nameCN":"Pharming Group N.V.","latestPrice":8.66,"timestamp":1743181298415,"preClose":8.47,"halted":0,"volume":1824,"delay":0,"floatShares":65852422,"shares":68030873,"eps":-0.27339,"marketStatus":"Trading","change":0.19,"latestTime":"03-28 13:31:13 EDT","open":8.66,"high":8.66,"low":8.66,"amount":15798.534048,"amplitude":0,"askPrice":8.85,"askSize":200,"bidPrice":8.59,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.27339,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"adrRate":10,"listingDate":1608699600000,"exchange":"NASDAQ","adjPreClose":8.47,"postHourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.65,"latestTime":"16:05 EDT","volume":1,"amount":8.47,"timestamp":1743105906025},"volumeRatio":0.9784},"requestUrl":"/m/hq/s/PHAR","defaultTab":"news","newsList":[{"id":"2522519244","title":"Pharming Group to participate in April investor conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2522519244","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522519244?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 15:00","pubTimestamp":1743145200,"startTime":"0","endTime":"0","summary":"Leiden, theNetherlands, March 28, 2025: Pharming Group N.V.   announces that Pharming’s management will participate in the following investor conferences in the month of April:. Van Lanschot Kempen Life Sciences Conference 2025, Amsterdam, NL, April 2-3, 2025. 24th Annual Needham Virtual Healthcare Conference, April 7-10, 2025Fabrice Chouraqui, Chief Executive Officer, and Anurag Relan, Chief Medical Officer, will present on Tuesday, April 8 at 10:15 am ET/16:15CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website.About Pharming Group N.V.Pharming Group N.V.  is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharming-group-participate-april-investor-070000671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHAR","PHGUF","BK4139"],"gpt_icon":0},{"id":"2520251465","title":"Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520251465","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520251465?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 23:25","pubTimestamp":1742484300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 11:25 ET (15:25 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAR"],"gpt_icon":0},{"id":"2520779021","title":"Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2520779021","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520779021?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 14:00","pubTimestamp":1742450400,"startTime":"0","endTime":"0","summary":"Multi-center clinical trial includes sites located in the US, UK and EU. Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies . CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million. Leiden, the Netherlands, March 20, 2025: Pharming Group N.V.   announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency  patients with immune dysregulation.CVID represents the largest group of symptomatic primary immunodeficiency  patients, where approximately 50% display autoimmune, lymphoproliferati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharming-group-announces-first-patient-060000736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHAR","PHGUF","PID","BK4139"],"gpt_icon":0},{"id":"2519872844","title":"Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2519872844","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519872844?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 18:54","pubTimestamp":1741949640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 14, 2025 06:54 ET (10:54 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAR"],"gpt_icon":0},{"id":"2519284428","title":"Pharming Group (PHGUF) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2519284428","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519284428?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 15:04","pubTimestamp":1741935844,"startTime":"0","endTime":"0","summary":"Full-Year Revenue: Increased by 21% to $297 million.Joenja Revenue: Increased by 147% to $45 million.Q4 Revenue Growth: 14% increase compared to Q4 2023.Gross Profit Growth: Increased by 9% despite a one-off inventory impairment.Operating Profit: Increased by $5.6 million, marking the second consecutive quarter of operating profit.Net Profit: Transitioned from a loss in Q4 2023 to a net profit in Q4 2024.Operating Cash Flow: Positive for the second consecutive quarter.2025 Revenue Guidance: Expected between $315 million and $335 million, indicating a growth rate of 6% to 13%.Operating Expenses: Expected to remain flat in 2025, excluding Abliva-related costs.Abliva Acquisition Cost: $66.1 million, funded with available cash.GuruFocus has detected 3 Warning Signs with PHGUF.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Pharming Group  reported a 21% increase in full-year 2024 revenues, reaching $297 million, surpassing their guidance ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharming-group-phguf-q4-2024-070404673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHAR","PHGUF"],"gpt_icon":0},{"id":"2519843852","title":"3 European Penny Stocks With Market Caps Over €300M","url":"https://stock-news.laohu8.com/highlight/detail?id=2519843852","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519843852?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 13:05","pubTimestamp":1741928710,"startTime":"0","endTime":"0","summary":"The European market has recently experienced a slight downturn, with the pan-European STOXX Europe 600 Index ending lower amid ongoing uncertainty about U.S. trade policy. Despite these challenges, there remains significant interest in penny stocks—a term that may seem outdated but continues to highlight opportunities for growth within smaller or newer companies. These stocks can be particularly attractive when they exhibit strong financial health and fundamentals, offering potential upside without some of the typical risks associated with this segment of the market.Click here to see the full list of 433 stocks from our European Penny Stocks screener.Operations: The company's revenue is segmented as follows: 36","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-european-penny-stocks-market-050510009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHGUF","BK4139","PHAR"],"gpt_icon":0},{"id":"2519070397","title":"Pharming Q4 2024 GAAP EPADS $0.05 Beats $0.01 Estimate, Sales $92.70M Beat $80.74M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2519070397","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519070397?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 14:19","pubTimestamp":1741846757,"startTime":"0","endTime":"0","summary":"Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.01 by 400 percent. This is a 225 percent increase over losses of $(0.04) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44295092/pharming-q4-2024-gaap-epads-0-05-beats-0-01-estimate-sales-92-70m-beat-80-74m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Pharming Q4 2024 GAAP EPADS $0.05 Beats $0.01 Estimate, Sales $92.70M Beat $80.74M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAR"],"gpt_icon":0},{"id":"2518776843","title":"Pharming Group NV  expected to post earnings of 1 cent a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2518776843","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518776843?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 14:02","pubTimestamp":1741672940,"startTime":"0","endTime":"0","summary":"Pharming Group NV  expected to post earnings of 1cent a share - Earnings Preview Pharming Group NV PHAR.OQ, PHAR.O is expected to show a fall in quarterly revenue when it reports  results on March 13 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nL8N3PU065:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAR"],"gpt_icon":0},{"id":"2516677509","title":"Pharming Group Shareholders Approve Fabrice Chouraqui's Appointment as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677509","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516677509?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:48","pubTimestamp":1741099720,"startTime":"0","endTime":"0","summary":"Pharming Group  said Tuesday that shareholders have approved the appointment of Fabrice Chouraqui as executive director and chief executive officer for a four-year term.Chouraqui succeeds Sijmen de Vries with immediate effect as a result of the approval, the company said.Pharming said de Vries will remain an advisor to the CEO until yearend to ensure a smooth transition.Price: 9.15, Change: +0.01, Percent Change: +0.11","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHAR","BK4139"],"gpt_icon":0},{"id":"2516742706","title":"Press Release: Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2516742706","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516742706?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:15","pubTimestamp":1741097700,"startTime":"0","endTime":"0","summary":"Leiden, the Netherlands, March 4, 2025: Pharming Group N.V.   announces today that the Extraordinary General Meeting of Shareholders  has adopted all proposals on the EGM agenda.Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years.As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025.In addition, shareholders also approved the proposal to approve certain components of the remuneration package of Mr. Chouraqui in his capacity as Executive Director and Chief Executive Officer.Pharming Group N.V.  is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PHAR"],"gpt_icon":0},{"id":"2514655318","title":"Pharming Group to participate in March investor conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2514655318","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514655318?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 15:00","pubTimestamp":1740726000,"startTime":"0","endTime":"0","summary":"Leiden, theNetherlands, February 28, 2025: Pharming Group N.V.   announces that Pharming’s management will participate in the following investor conference in the month of March:. 37th Annual Roth Conference, Dana Point, CA, USA, March 16-18, 2025Anurag Relan, Chief Medical Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Monday, March 17 at 01:30pm PT/21:30 CET.For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Roth representative.About Pharming Group N.V.Pharming Group N.V.  is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, includ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharming-group-participate-march-investor-070000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHGUF","PHAR","BK4139"],"gpt_icon":0},{"id":"2514840020","title":"Pharming Group to report fourth quarter and full year 2024 financial results on March 13","url":"https://stock-news.laohu8.com/highlight/detail?id=2514840020","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514840020?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 15:00","pubTimestamp":1740639600,"startTime":"0","endTime":"0","summary":"Leiden, the Netherlands, February 27, 2025:Pharming Group N.V.   confirms it will report its preliminary  fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025.Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 13, 2025.To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.To watch the live webcast, please register in advance using the link below.About Pharming Group N.V.Pharming Group N.V.  is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharming-group-report-fourth-quarter-070000461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHGUF","PHAR","BK4139"],"gpt_icon":0},{"id":"2510386085","title":"High Growth Tech And These 3 Dynamic Stocks with Promising Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2510386085","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510386085?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 21:02","pubTimestamp":1739278930,"startTime":"0","endTime":"0","summary":"Recent global market developments have been marked by tariff uncertainties and mixed economic signals, with U.S. stocks experiencing a decline amid trade tensions and cooling job growth, while European markets showed resilience against similar concerns. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate strong earnings potential and adaptability to shifting market dynamics.Overview: Pharming Group N.V. is a biopharmaceutical company focused on developing and commercializing protein replacement therapies and precision medicines for rare diseases across the United States, Europe, and internationally, with a market cap of approximately 568.06 million.Operations: The company generates revenue primarily from its Recombinant Human C1 Esterase Inhibitor business, which reported $285.75 million. Its focus is on developing and commercializing therapies for rare diseases, targeting markets in the United States, Europe, and internationally.Over","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-3-dynamic-130210703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PHAR","PHGUF"],"gpt_icon":0},{"id":"2510889251","title":"Pharming Group to participate in February investor conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2510889251","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510889251?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 15:00","pubTimestamp":1739170800,"startTime":"0","endTime":"0","summary":"Leiden, theNetherlands, February 10, 2025: Pharming Group N.V.   announces that Pharming’s management will participate in the following investor conference in the month of February:. Oppenheimer 35th Annual Healthcare Life Sciences Conference, Virtual, February 11-12, 2025Sijmen de Vries, Chief Executive Officer and Anurag Relan, Chief Medical Officer, will present on Wednesday, February 12 at 08:40 ET/14:40 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website.About Pharming Group N.V.Pharming Group N.V.  is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharming-group-participate-february-investor-070000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PHGUF","PHAR"],"gpt_icon":0},{"id":"2509779165","title":"Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period","url":"https://stock-news.laohu8.com/highlight/detail?id=2509779165","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509779165?lang=en_us&edition=full_marsco","pubTime":"2025-02-08 05:00","pubTimestamp":1738962000,"startTime":"0","endTime":"0","summary":"This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer  must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this press release and in the offer document published on the transaction website . Shareholders in the United States should also refer to the section titled “Special notice to shareholders in the United States” at the end of this press release.To enable the remaining shareholders of Abliva who have not tendered their shares to accept the Offer, Pharming has decided to extend the acceptance period until February 20, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharming-technologies-b-v-declares-210000866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AB","LU0128526141.USD","BK4590","PHAR","LU0029874061.USD","BK4135","PHGUF","BK4598","NEVPF","BK4139"],"gpt_icon":0},{"id":"2508160114","title":"Penny Stock Opportunities: 3 Picks With Market Caps As Low As US$20M","url":"https://stock-news.laohu8.com/highlight/detail?id=2508160114","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508160114?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 13:06","pubTimestamp":1738559210,"startTime":"0","endTime":"0","summary":"Global markets have recently experienced significant volatility, with U.S. stocks mostly lower due to AI competition fears and ongoing tariff risks, while European equities were buoyed by strong earnings and an ECB rate cut. In this context of fluctuating market conditions, investors might find opportunities in lesser-known areas such as penny stocks. Though the term 'penny stocks' may seem outdated, these investments—typically in smaller or newer companies—can still offer potential for growth when they are supported by solid financial fundamentals.Overview: Hang Pin Living Technology Company Limited is an investment holding company involved in garment sourcing and financial services in the People’s Republic o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/penny-stock-opportunities-3-picks-050650347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PHGUF","PHAR"],"gpt_icon":0},{"id":"2507693809","title":"Avalanche TVL Hits $1.74B: Top 10 Projects Dominating the Ecosystem","url":"https://stock-news.laohu8.com/highlight/detail?id=2507693809","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507693809?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 08:17","pubTimestamp":1738196240,"startTime":"0","endTime":"0","summary":"The Total Value Locked on Avalanche blockchain passed $1.74 billion, marking a major network advancement. The industry momentum of decentralized finance (DeFi) further verifies the Avalanche network’s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/679ac510d93afe6c6e9edb5c/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["JOE","BK4193","AAVE.USD.HKCC","AAVE.USD.CC","BK4139","PHAR","AVAX.USD.CC","AVAX.USD.HKCC"],"gpt_icon":0},{"id":"2505661209","title":"Pharming Group to convene Extraordinary General Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2505661209","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505661209?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 01:00","pubTimestamp":1737478800,"startTime":"0","endTime":"0","summary":"The EGM is convened for the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years, based on a binding nomination by the Board of Directors. Mr. Chouraqui will be successor to Mr. Sijmen de Vries, subject to  his appointment as Executive Director and Chief Executive Officer at the EGM.The EGM will be held as a physical meeting at the Corpus Congress Centre, Willem Einthovenstraat 1, 2342 BH in Oegstgeest, the Netherlands. Our shareholders are invited to attend the EGM in person or to follow the meeting through our live webcast.Inside InformationThis press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7 of the EU Market Abuse Regulation.LifeSpring Life Sciences Communication, Amsterdam, the NetherlandsLeon MelensT: +31 6 53 81 64 27E: pharming@lifespring.nl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharming-group-convene-extraordinary-general-170000239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHGUF","PHAR","BK4139"],"gpt_icon":0},{"id":"2505406248","title":"Pharming Group's Board Nominates Fabrice Chouraqui as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2505406248","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505406248?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 16:56","pubTimestamp":1737449764,"startTime":"0","endTime":"0","summary":"Pharming Group (PHAR) said Tuesday its board has nominated Fabrice Chouraqui as chief executive officer for a term of four years, succeeding Sijmen de Vries.De Vries will remain as a strategic advisor until Dec. 31.Chouraqui was recently a CEO-Partner at Flagship Pioneering.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHAR","BK4139"],"gpt_icon":0},{"id":"2505297175","title":"Press Release: Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505297175","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505297175?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 14:00","pubTimestamp":1737439200,"startTime":"0","endTime":"0","summary":"Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer. Leiden, the Netherlands, January 21, 2025: Pharming Group N.V.   announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming's new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries.\"I am very pleased with the nomination of Fabrice Chouraqui as my successor. Fabrice brings strong leadership experience with global pharmaceutical companies and highly innovative biotechnology companies to Pharming. To make way for Fabrice to take over the executive leadership of the Company, I will resign from the Board of Directors upon the appointment of Fabrice by our shareholders. I look forward to supporting Fabrice, working closely together through the remainder of the year, and ensuring a smooth hand-over.\". \"I am honored to have the opportunity to take over the leadership of Pharming, building on the strong foundation and ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharming.com","stockEarnings":[{"period":"1week","weight":-0.0308},{"period":"1month","weight":-0.0515},{"period":"3month","weight":-0.1536},{"period":"6month","weight":0.0188},{"period":"1year","weight":-0.202},{"period":"ytd","weight":-0.1406}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.028542},{"month":2,"riseRate":0,"avgChangeRate":-0.055174},{"month":3,"riseRate":0.4,"avgChangeRate":0.010286},{"month":4,"riseRate":0.25,"avgChangeRate":-0.094045},{"month":5,"riseRate":0.25,"avgChangeRate":-0.014609},{"month":6,"riseRate":0.25,"avgChangeRate":-0.027884},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003345},{"month":8,"riseRate":0.25,"avgChangeRate":0.104626},{"month":9,"riseRate":0.25,"avgChangeRate":-0.082206},{"month":10,"riseRate":0.5,"avgChangeRate":0.013119},{"month":11,"riseRate":0.25,"avgChangeRate":-0.005504},{"month":12,"riseRate":0.5,"avgChangeRate":0.089041}],"exchange":"NASDAQ","name":"Pharming Group N.V.","nameEN":"Pharming Group N.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharming Group N.V.(PHAR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharming Group N.V.(PHAR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharming Group N.V.,PHAR,Pharming Group N.V.股票,Pharming Group N.V.股票老虎,Pharming Group N.V.股票老虎国际,Pharming Group N.V.行情,Pharming Group N.V.股票行情,Pharming Group N.V.股价,Pharming Group N.V.股市,Pharming Group N.V.股票价格,Pharming Group N.V.股票交易,Pharming Group N.V.股票购买,Pharming Group N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharming Group N.V.(PHAR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharming Group N.V.(PHAR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction